Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kite, Humanigen to evaluate Yescarta, Lenzilumab combo in relapsed/refractory DLBCL
The objective of this study is to determine the effect of lenzilumab on the safety of Yescarta. Kite will act as the sponsor of this study and will
The objective of this study is to determine the effect of lenzilumab on the safety of Yescarta. Kite will act as the sponsor of this study and will
Final data announced today from a 24-week Phase 3 study in people with one F508del mutation and one minimal function mutation and from a 4-week Phase 3 study
It will bring together Gubra’s established expertise in the design, synthesis, pharmaceutical characterization and in vivo testing of therapeutic peptides with Boehringer Ingelheim’s expertise in the research and
Souvien is founded on the pioneering research of Professor Li-Huei Tsai, the director of The Picower Institute for Learning and Memory at MIT, and Associate Professor Stephen Haggarty,
The Swiss pharma company is looking for a conditional marketing authorization (CMA) for idebenone for DMD patients who are not using glucocorticoids for the treatment of their respiratory
CNTX-0290 is a small molecule somatostatin receptor type 4 (SSTR4) agonist, which is being evaluated for the treatment of chronic pain conditions in a phase 1 clinical trial.
The settlement resolves the state’s claims against Teva. The settlement does not establish any wrongdoing on the part of the company; Teva has not contributed to the abuse
Lyrica could not show a statistically significant reduction in seizure frequency in comparison to placebo in the late-stage trial held in 219 patients aged between five and 65
KCNQ2-NEE, a rare infant genetic epilepsy, results from mutations in genes encoding the Kv7.2/Kv7.3 ion channel, leading to frequent seizures and profound developmental delay. The preclinical data were
The licensing rights of Raxone to Chiesi Group will be applicable in all countries with the exception of the US and Canada and in LHON and all other